Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
MediumReport
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
MediumReport
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.
LowReport
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $19.00 price target on the stock.
LowReport
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $19.00 price target on the stock.
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
MediumReport
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: